Adherex Technologies (FENC) Competitors $9.93 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$9.93 0.00 (0.00%) As of 05/22/2026 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock FENC vs. BCAX, BHVN, AVBP, SEPN, and MLTXShould you buy Adherex Technologies stock or one of its competitors? MarketBeat compares Adherex Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adherex Technologies include Bicara Therapeutics (BCAX), Biohaven (BHVN), ArriVent BioPharma (AVBP), Septerna (SEPN), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. FENC vs. BCAXFENC vs. BHVNFENC vs. AVBPFENC vs. SEPNFENC vs. MLTXHow does Adherex Technologies compare to Bicara Therapeutics?Adherex Technologies (NASDAQ:FENC) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation. Which has more volatility & risk, FENC or BCAX? Adherex Technologies has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.57, meaning that its share price is 157% less volatile than the broader market. Does the media favor FENC or BCAX? In the previous week, Adherex Technologies had 2 more articles in the media than Bicara Therapeutics. MarketBeat recorded 14 mentions for Adherex Technologies and 12 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.10 beat Adherex Technologies' score of -0.27 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adherex Technologies 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Bicara Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Is FENC or BCAX more profitable? Bicara Therapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -17.12%. Bicara Therapeutics' return on equity of -35.89% beat Adherex Technologies' return on equity.Company Net Margins Return on Equity Return on Assets Adherex Technologies-17.12% -43.87% -11.35% Bicara Therapeutics N/A -35.89%-33.78% Do institutionals & insiders hold more shares of FENC or BCAX? 55.5% of Adherex Technologies shares are owned by institutional investors. 10.7% of Adherex Technologies shares are owned by company insiders. Comparatively, 15.5% of Bicara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend FENC or BCAX? Adherex Technologies currently has a consensus price target of $15.40, suggesting a potential upside of 55.09%. Bicara Therapeutics has a consensus price target of $30.27, suggesting a potential upside of 39.63%. Given Adherex Technologies' higher possible upside, analysts clearly believe Adherex Technologies is more favorable than Bicara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adherex Technologies 2 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.57Bicara Therapeutics 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.71 Which has preferable earnings & valuation, FENC or BCAX? Adherex Technologies has higher revenue and earnings than Bicara Therapeutics. Adherex Technologies is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdherex Technologies$44.64M7.68-$9.74M-$0.29N/ABicara TherapeuticsN/AN/A-$137.95M-$2.78N/A SummaryAdherex Technologies beats Bicara Therapeutics on 8 of the 15 factors compared between the two stocks.How does Adherex Technologies compare to Biohaven?Adherex Technologies (NASDAQ:FENC) and Biohaven (NYSE:BHVN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings. Which has more risk & volatility, FENC or BHVN? Adherex Technologies has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Biohaven has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Does the media refer more to FENC or BHVN? In the previous week, Adherex Technologies had 13 more articles in the media than Biohaven. MarketBeat recorded 14 mentions for Adherex Technologies and 1 mentions for Biohaven. Biohaven's average media sentiment score of 0.59 beat Adherex Technologies' score of -0.27 indicating that Biohaven is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adherex Technologies 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Biohaven 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer FENC or BHVN? Adherex Technologies presently has a consensus target price of $15.40, suggesting a potential upside of 55.09%. Biohaven has a consensus target price of $22.27, suggesting a potential upside of 135.75%. Given Biohaven's stronger consensus rating and higher probable upside, analysts clearly believe Biohaven is more favorable than Adherex Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adherex Technologies 2 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.57Biohaven 1 Sell rating(s) 5 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.71 Is FENC or BHVN more profitable? Biohaven has a net margin of 0.00% compared to Adherex Technologies' net margin of -17.12%. Adherex Technologies' return on equity of -43.87% beat Biohaven's return on equity.Company Net Margins Return on Equity Return on Assets Adherex Technologies-17.12% -43.87% -11.35% Biohaven N/A -866.46%-137.99% Which has better earnings & valuation, FENC or BHVN? Adherex Technologies has higher revenue and earnings than Biohaven. Adherex Technologies is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdherex Technologies$44.64M7.68-$9.74M-$0.29N/ABiohavenN/AN/A-$738.82M-$5.67N/A Do insiders & institutionals believe in FENC or BHVN? 55.5% of Adherex Technologies shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 10.7% of Adherex Technologies shares are held by company insiders. Comparatively, 13.8% of Biohaven shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryBiohaven beats Adherex Technologies on 10 of the 16 factors compared between the two stocks.How does Adherex Technologies compare to ArriVent BioPharma?Adherex Technologies (NASDAQ:FENC) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends. Is FENC or AVBP more profitable? ArriVent BioPharma has a net margin of 0.00% compared to Adherex Technologies' net margin of -17.12%. Adherex Technologies' return on equity of -43.87% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Adherex Technologies-17.12% -43.87% -11.35% ArriVent BioPharma N/A -48.98%-45.44% Which has more risk & volatility, FENC or AVBP? Adherex Technologies has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market. Which has higher earnings and valuation, FENC or AVBP? Adherex Technologies has higher revenue and earnings than ArriVent BioPharma. Adherex Technologies is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdherex Technologies$44.64M7.68-$9.74M-$0.29N/AArriVent BioPharmaN/AN/A-$166.31M-$3.47N/A Do analysts recommend FENC or AVBP? Adherex Technologies currently has a consensus price target of $15.40, suggesting a potential upside of 55.09%. ArriVent BioPharma has a consensus price target of $43.13, suggesting a potential upside of 61.34%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe ArriVent BioPharma is more favorable than Adherex Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adherex Technologies 2 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.57ArriVent BioPharma 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.91 Do insiders and institutionals hold more shares of FENC or AVBP? 55.5% of Adherex Technologies shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 10.7% of Adherex Technologies shares are owned by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to FENC or AVBP? In the previous week, Adherex Technologies had 13 more articles in the media than ArriVent BioPharma. MarketBeat recorded 14 mentions for Adherex Technologies and 1 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.00 beat Adherex Technologies' score of -0.27 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adherex Technologies 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAdherex Technologies and ArriVent BioPharma tied by winning 8 of the 16 factors compared between the two stocks.How does Adherex Technologies compare to Septerna?Septerna (NASDAQ:SEPN) and Adherex Technologies (NASDAQ:FENC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability. Is SEPN or FENC more profitable? Adherex Technologies has a net margin of -17.12% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Adherex Technologies' return on equity.Company Net Margins Return on Equity Return on Assets Septerna-49.88% -12.72% -8.87% Adherex Technologies -17.12%-43.87%-11.35% Do analysts recommend SEPN or FENC? Septerna currently has a consensus price target of $43.13, suggesting a potential upside of 52.06%. Adherex Technologies has a consensus price target of $15.40, suggesting a potential upside of 55.09%. Given Adherex Technologies' higher possible upside, analysts plainly believe Adherex Technologies is more favorable than Septerna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80Adherex Technologies 2 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.57 Which has more volatility & risk, SEPN or FENC? Septerna has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market. Comparatively, Adherex Technologies has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Does the media favor SEPN or FENC? In the previous week, Adherex Technologies had 14 more articles in the media than Septerna. MarketBeat recorded 14 mentions for Adherex Technologies and 0 mentions for Septerna. Septerna's average media sentiment score of 0.00 beat Adherex Technologies' score of -0.27 indicating that Septerna is being referred to more favorably in the media. Company Overall Sentiment Septerna Neutral Adherex Technologies Neutral Which has better valuation and earnings, SEPN or FENC? Adherex Technologies has lower revenue, but higher earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Adherex Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSepterna$45.95M27.82-$48.88M-$0.81N/AAdherex Technologies$44.64M7.68-$9.74M-$0.29N/A Do insiders & institutionals hold more shares of SEPN or FENC? 55.5% of Adherex Technologies shares are held by institutional investors. 4.3% of Septerna shares are held by insiders. Comparatively, 10.7% of Adherex Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummarySepterna and Adherex Technologies tied by winning 8 of the 16 factors compared between the two stocks.How does Adherex Technologies compare to MoonLake Immunotherapeutics?MoonLake Immunotherapeutics (NASDAQ:MLTX) and Adherex Technologies (NASDAQ:FENC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends. Which has more volatility and risk, MLTX or FENC? MoonLake Immunotherapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, Adherex Technologies has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Is MLTX or FENC more profitable? MoonLake Immunotherapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -17.12%. Adherex Technologies' return on equity of -43.87% beat MoonLake Immunotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MoonLake ImmunotherapeuticsN/A -85.15% -60.52% Adherex Technologies -17.12%-43.87%-11.35% Which has higher earnings & valuation, MLTX or FENC? Adherex Technologies has higher revenue and earnings than MoonLake Immunotherapeutics. Adherex Technologies is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoonLake ImmunotherapeuticsN/AN/A-$227.32M-$3.87N/AAdherex Technologies$44.64M7.68-$9.74M-$0.29N/A Do analysts recommend MLTX or FENC? MoonLake Immunotherapeutics presently has a consensus target price of $23.85, suggesting a potential upside of 31.09%. Adherex Technologies has a consensus target price of $15.40, suggesting a potential upside of 55.09%. Given Adherex Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Adherex Technologies is more favorable than MoonLake Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MoonLake Immunotherapeutics 3 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.38Adherex Technologies 2 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.57 Do institutionals and insiders hold more shares of MLTX or FENC? 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 10.7% of Adherex Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor MLTX or FENC? In the previous week, Adherex Technologies had 9 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 14 mentions for Adherex Technologies and 5 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 1.01 beat Adherex Technologies' score of -0.27 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adherex Technologies 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAdherex Technologies beats MoonLake Immunotherapeutics on 9 of the 16 factors compared between the two stocks. Get Adherex Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FENC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FENC vs. The Competition ExportMetricAdherex TechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$342.98M$3.37B$6.43B$12.32BDividend YieldN/A2.26%2.76%5.28%P/E Ratio-34.2418.9121.0125.66Price / Sales7.68329.35615.84111.99Price / CashN/A125.1743.4956.67Price / Book9.117.0910.377.14Net Income-$9.74M$24.45M$3.57B$335.98M7 Day Performance3.44%5.45%6.01%3.56%1 Month Performance45.18%2.43%3.52%2.54%1 Year Performance26.18%62.98%34.13%35.05% Adherex Technologies Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FENCAdherex Technologies3.8134 of 5 stars$9.93flat$15.40+55.1%+26.2%$342.98M$44.64MN/A10Analyst ForecastAnalyst RevisionGap UpBCAXBicara Therapeutics2.4508 of 5 stars$20.84+2.0%$30.27+45.3%+133.9%$1.34BN/AN/A32Analyst UpgradeGap UpBHVNBiohaven2.589 of 5 stars$9.49+7.2%$22.27+134.7%-39.7%$1.33BN/AN/A239AVBPArriVent BioPharma2.3889 of 5 stars$27.00-0.8%$43.13+59.7%+31.0%$1.27BN/AN/A40Analyst ForecastSEPNSepterna2.8631 of 5 stars$27.92-0.3%$43.13+54.5%+208.6%$1.26B$45.95MN/AN/A Related Companies and Tools Related Companies Bicara Therapeutics Alternatives Biohaven Alternatives ArriVent BioPharma Alternatives Septerna Alternatives MoonLake Immunotherapeutics Alternatives Olema Pharmaceuticals Alternatives Calliditas Therapeutics AB (publ) Alternatives WAVE Life Sciences Alternatives Avalyn Pharma Alternatives Maplight Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FENC) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adherex Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adherex Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
